Opportunity Information: Apply for PAR 13 389
Apply for PAR 13 389
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Nov 7, 2013 and posted on Nov 7, 2013.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public housing authorities/Indian housing authorities For profit organizations other than small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public and State controlled institutions of higher education Small businesses County governments Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) State governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)" (Funding Opportunity Number PAR-13-389) is an NIH discretionary research grant designed to push forward the discovery of biological mechanisms behind diseases that arise during pregnancy or are triggered by pregnancy. Its central goal is to stimulate R01-level projects that do more than describe pregnancy-related disorders in general terms. Instead, the FOA is aimed at studies that pinpoint specific molecular targets and use that information to support the creation or advancement of safer, more effective therapeutics that can be used during pregnancy, where medication safety and fetal considerations often limit treatment options.
This opportunity sits within the NIH mission space and is tied to the Child Health and Human Development Extramural Research program (CFDA 93.865). It supports health-focused research, and it is structured as a standard NIH research project grant (R01), meaning applicants are expected to propose a well-developed, hypothesis-driven research plan with clear aims, strong preliminary rationale, and a credible path toward target identification and therapeutic development. Cost sharing or matching is not required, which aligns with typical NIH investigator-initiated research support and lowers administrative barriers for applicants.
The FOA was posted and created on November 7, 2013, and it carried an original and current closing date of May 7, 2017, with an archive date of June 7, 2017. In practical terms, those dates indicate this is an archived funding opportunity that is no longer accepting applications, but it remains useful as a reference for understanding NIH priorities in pregnancy pharmacology and for shaping future applications under similar or successor announcements.
Eligibility is broad and includes many common U.S.-based applicant organization types across government, academia, nonprofit, and industry. Eligible applicants listed include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with and without 501(c)(3) status (with the usual NIH distinctions), for-profit organizations other than small businesses, and small businesses. It also includes a wide range of governmental entities such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities including Indian housing authorities. The FOA also explicitly expands eligibility to organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, and eligible federal agencies. Importantly, non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply as the applicant organization, though foreign components as defined under the NIH Grants Policy Statement are allowed, which can enable international collaborations or specific overseas elements within an otherwise U.S.-led application.
From a scientific standpoint, the emphasis on "molecular targets" signals that NIH was looking for proposals that identify actionable nodes in pathways driving pregnancy-associated or pregnancy-induced disease, such as receptors, enzymes, signaling intermediates, transporters, or gene regulatory mechanisms that can be modulated with drugs or biologics. The second half of the title and description, focused on development of therapeutics to prevent or treat these diseases, indicates the intent to move beyond purely descriptive biology. Applicants were expected to connect mechanistic insight to therapeutic strategy, for example through validation of targets, proof-of-concept studies, screening or optimization of candidate compounds, or other translational steps consistent with an R01 scope. The repeated focus on "safer and more effective medications for use in pregnancy" reflects a longstanding clinical gap: many drugs are under-studied in pregnant populations, and pregnancy physiology can change drug absorption, distribution, metabolism, and excretion, while fetal safety considerations can limit what clinicians are willing to prescribe. This FOA is essentially an attempt to grow a pipeline of pregnancy-appropriate interventions by starting with strong molecular understanding and translating that into therapeutic directions that could ultimately improve maternal and fetal outcomes.
The sponsoring agency is the National Institutes of Health. For applicants or readers who wanted the full text during its active period, NIH provided an announcement link (http://grants.nih.gov/grants/guide/pa-files/PAR-13-389.html). Technical issues related to accessing the announcement were directed to the NIH Office of Extramural Research (OER) webmaster contact (FBOWebmaster@OD.NIH.GOV), which reflects NIH's standard support channel for FOA access and linking problems rather than scientific programmatic questions.
Overall, PAR-13-389 can be summarized as an NIH R01 funding announcement encouraging rigorous, mechanistically grounded research focused on discovering druggable molecular targets in pregnancy-related or pregnancy-induced disorders and translating those targets into therapeutic development strategies, with broad U.S.-based organizational eligibility, no cost-sharing requirement, and allowance for foreign components under NIH policy even though foreign institutions could not serve as the primary applicant.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)" and the Funding Opportunity Number is PAR-13-389.
Which agency sponsors this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What type of grant mechanism is this?
This is an NIH research project grant (R01). That structure generally indicates an expectation of a well-developed, hypothesis-driven research plan with clear aims and a credible path to achieving the proposed scientific goals.
What is the main purpose of PAR-13-389?
The central purpose is to push forward discovery of biological mechanisms behind diseases that arise during pregnancy or are triggered by pregnancy, with an emphasis on identifying specific molecular targets and using that information to support development or advancement of therapeutics that are safer and more effective for use during pregnancy.
What does NIH mean by emphasizing "molecular targets" in this FOA?
Based on the description provided, "molecular targets" refers to actionable points in the disease pathway that could be modulated therapeutically, such as receptors, enzymes, signaling intermediates, transporters, or gene regulatory mechanisms.
Is this opportunity focused on describing pregnancy-related disorders, or something more specific?
It is aimed at projects that go beyond general or purely descriptive characterization of pregnancy-related disorders. The intent is to pinpoint specific molecular targets and connect mechanistic insight to therapeutic development.
How translational is the expected research under this FOA?
The FOA is explicitly oriented toward translating mechanistic findings into therapeutic directions. Examples mentioned include target validation, proof-of-concept studies, screening or optimization of candidate compounds, and other translational steps consistent with an R01 scope.
Why is there a special emphasis on therapeutics that can be used during pregnancy?
The FOA highlights a clinical gap: medication safety and fetal considerations often limit treatment options during pregnancy, and many drugs are under-studied in pregnant populations. It also notes that pregnancy physiology can change drug absorption, distribution, metabolism, and excretion.
Which NIH mission/program area is this associated with?
It is tied to the Child Health and Human Development Extramural Research program, CFDA 93.865.
Is cost sharing or matching required?
No. The FOA states that cost sharing or matching is not required.
Is this funding opportunity still open for applications?
No. The FOA is described as archived and no longer accepting applications. It was posted/created on November 7, 2013, had an original and current closing date of May 7, 2017, and an archive date of June 7, 2017.
What is the value of this FOA if it is archived?
As described, it remains useful as a reference for understanding NIH priorities in pregnancy pharmacology and for shaping future applications under similar or successor announcements.
Who is eligible to apply (organizational eligibility)?
Eligibility is described as broad and includes many U.S.-based organization types across academia, nonprofit, industry, and government. Examples listed include public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses.
Are government entities eligible to apply?
Yes. Eligible applicants listed include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities including Indian housing authorities.
Are minority-serving institutions and similar organizations explicitly included?
Yes. The FOA explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. The eligibility list explicitly mentions faith-based or community-based organizations, as well as regional organizations.
Can federal agencies apply?
Yes. The FOA indicates eligible federal agencies are included among eligible applicants.
Can a non-U.S. (foreign) institution apply as the main applicant organization?
No. The FOA states that non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply as the applicant organization.
Are foreign components allowed in a U.S.-led application?
Yes. The FOA notes that foreign components, as defined under the NIH Grants Policy Statement, are allowed, which can support international collaborations or overseas elements within an otherwise U.S.-led application.
Where can I find the full NIH announcement text for PAR-13-389?
The NIH announcement link provided is: http://grants.nih.gov/grants/guide/pa-files/PAR-13-389.html
Who should be contacted for technical issues accessing the announcement link?
Technical issues related to accessing the announcement were directed to the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the simplest summary of what PAR-13-389 aimed to fund?
It aimed to fund rigorous R01 research that identifies druggable molecular targets in pregnancy-related or pregnancy-induced diseases and translates those targets into therapeutic development strategies, with broad U.S.-based eligibility, no cost sharing requirement, and allowance for foreign components under NIH policy.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42)
Previous opportunity: Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 389
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 389) also looked into and applied for these:
| Funding Opportunity |
|---|
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Data Sharing for Demographic Research Infrastructure Program (U24) Apply for RFA HD 14 015 Funding Number: RFA HD 14 015 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2014 (U54) Apply for RFA HD 14 012 Funding Number: RFA HD 14 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Population Dynamics Centers Research Infrastructure (P2C) Apply for RFA HD 14 016 Funding Number: RFA HD 14 016 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network (U01) Apply for RFA HD 14 020 Funding Number: RFA HD 14 020 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Pediatric Critical Care Research Network (UG1) Apply for RFA HD 14 022 Funding Number: RFA HD 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) Apply for RFA AI 14 008 Funding Number: RFA AI 14 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R43) Apply for RFA HD 15 008 Funding Number: RFA HD 15 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41) Apply for RFA HD 15 007 Funding Number: RFA HD 15 007 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Male Contraceptive Development Program (U01) Apply for RFA HD 14 034 Funding Number: RFA HD 14 034 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Global Omics Approaches Targeting Adverse Pregnancy and Neonatal Outcomes Utilizing Existing Cohorts (R01) Apply for PAR 14 264 Funding Number: PAR 14 264 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Peripheral Blood Biomarkers of Chronic Traumatic Brain Injury in Human Subjects SBIR Direct Phase II (R44) Apply for RFA HD 15 012 Funding Number: RFA HD 15 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 14 269 Funding Number: PAR 14 269 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R03) Apply for PAR 14 271 Funding Number: PAR 14 271 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children (R01) Apply for PAR 14 274 Funding Number: PAR 14 274 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medically Assisted Reproduction Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01) Apply for PAR 14 272 Funding Number: PAR 14 272 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medically Assisted Reproduction Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R21) Apply for PAR 14 273 Funding Number: PAR 14 273 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 389", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.